Trautec pioneers animal-free recombinant human collagen produced through advanced bio fermentation process. These innovative biomaterials offer high biocompatibility, stability and efficacy for next-generation skin and hair care formulations.
Trautec is a biotechnology company specialized in the development and production of recombinant human collagen biomaterials designed for biomedical applications. Founded with the mission of developing high-performance collagen, the company focuses on the research, large-scale production, and its commercialization.
At the core of Trautec’s innovation lies its technology leading to SRHC (Synthetic Recombinant Human Collagen), produced through controlled biosynthesis using eukaryotic yeast fermentation. Unlike conventional collagen derived from animal sources, recombinant collagen offers high purity, excellent biocompatibility, and improved stability, while eliminating risks related to animal contaminants or allergens.
Trautec’s portfolio includes advanced active ingredients namely ReCol1®, ReCol2®, ReCol3® and ReCol17®, designed to support skin regeneration, improve elasticity, and promote scalp health and hair follicle vitality. These bioengineered collagen fragments mimic the structure and functionality of natural human collagen, enabling more effective interaction with skin cells and supporting processes such as dermal repair, barrier reinforcement, and tissue regeneration.
Thanks to its strong research and development capabilities and a robust intellectual property portfolio, Trautec has positioned itself at the forefront of recombinant human collagen technology. The company continues to expand the applications of its biomaterials across multiple fields, including skincare, regenerative, and aesthetic medicine.
By combining cutting-edge production platform with a commitment to safety and sustainability, Trautec contributes to shaping the future of medical device ingredients, offering formulators innovative solutions for next-generation skin and hair care products.
